Beta2-agonists and paresthesias in multiple sclerosis.
Axelrod
Sara
S
Bielory
Leonard
L
D000318:Adrenergic beta-Agonists / Q000009:adverse effects*; D000420:Albuterol / Q000009:adverse effects / Q000031:analogs & derivatives / Q000627:therapeutic use; D000547:Amantadine / Q000627:therapeutic use; D018712:Analgesics, Non-Narcotic / Q000627:therapeutic use; D000730:Androstadienes / Q000627:therapeutic use; D047072:Aromatase Inhibitors / Q000627:therapeutic use; D001249:Asthma / Q000150:complications* / Q000188:drug therapy*; D001993:Bronchodilator Agents / Q000009:adverse effects; D000077265:Donepezil; D004359:Drug Therapy, Combination; D005260:Female; D000068298:Fluticasone; D005512:Food Hypersensitivity / Q000150:complications; D006801:Humans; D007189:Indans / Q000627:therapeutic use; D007372:Interferons / Q000627:therapeutic use; D020315:Latex Hypersensitivity / Q000150:complications; D000077289:Letrozole; D008333:Mandelic Acids / Q000627:therapeutic use; D008875:Middle Aged; D009103:Multiple Sclerosis / Q000150:complications* / Q000188:drug therapy; D009330:Nebulizers and Vaporizers; D009570:Nitriles / Q000627:therapeutic use; D018697:Nootropic Agents / Q000627:therapeutic use; D010276:Parasympatholytics / Q000627:therapeutic use; D010292:Paresthesia / Q000139:chemically induced*; D010880:Piperidines / Q000627:therapeutic use; D012129:Respiratory Function Tests; D000068299:Salmeterol Xinafoate; D013974:Thyroxine / Q000627:therapeutic use; D014230:Triazoles / Q000627:therapeutic use
D000318:Adrenergic beta-Agonists; D018712:Analgesics, Non-Narcotic; D000730:Androstadienes; D047072:Aromatase Inhibitors; D001993:Bronchodilator Agents; D007189:Indans; D008333:Mandelic Acids; D009570:Nitriles; D018697:Nootropic Agents; D010276:Parasympatholytics; D010880:Piperidines; D014230:Triazoles; D000068299:Salmeterol Xinafoate; D000077289:Letrozole; D000077265:Donepezil; D007372:Interferons; D000547:Amantadine; D000068298:Fluticasone; C005419:oxybutynin; D013974:Thyroxine; D000420:Albuterol